AMZN
Amazon.com, Inc.
AMZN's fundamentals are mixed: revenue grew 15%, but free cash flow turned negative. Its PE of 22x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect strong earnings growth.
UCAR
U Power Limited
There isn't enough reported data to score UCAR yet.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
UCAR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
UCAR's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
UCAR PE Valuation
UCAR has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
UCAR Forward outlook
There aren't enough analyst estimates for UCAR to show an outlook.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over UCAR in the latest year-over-year earnings comparison.
UCAR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$728.48 | -$273.46 |
| Q4 2025 | -$451.71 | +$52.23 |
UCAR is still losing money, but far less than before: $728.48 per share over the past year, against $2,761.31 at its worst in late 2022.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN's revenue has grown year over year every quarter since late 2020: $202B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over UCAR on profitability, with a higher operating margin.
UCAR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.2M | -17% |
| Q4 2025 | $3.5M | -25% |
| Q2 2025 | $2.7M | +34% |
| Q4 2024 | $4.7M | +74% |
| Q2 2024 | $2M | +596% |
| Q4 2023 | $2.7M | +129% |
| Q4 2022 | $1.2M | +95% |
| Q4 2021 | $601K | +447% |
UCAR has the edge over AMZN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -542% | -342 points |
| Q4 2025 | -174% | -83 points |
| Q2 2025 | -98% | +984 points |
| Q4 2024 | -102% | +620 points |
| Q2 2024 | -200% | +361 points |
| Q4 2023 | -92% | +470 points |
| Q2 2023 | -1083% | +11 points |
| Q4 2022 | -722% | +372 points |
UCAR's operating margin was −542% last quarter, down 342 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
UCAR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2022 | -$3.1M | +$3.9M |
| Q4 2021 | -$7M | -$5.2M |
| Q2 2021 | -$7M | -$5.2M |
UCAR and AMZN do not have enough comparable growth data to identify a winner.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over UCAR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
UCAR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +2.3K shares |
| 1 year | +59% | +9.3K shares |
UCAR has 25,148 diluted shares, up 59% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $36M |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
UCAR Net Leverage
UCAR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
UCAR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 20.5 | Oversold |
| Stochastic | 3.2 | Oversold |
UCAR's weekly RSI is 21 (oversold) and its Stochastic is 3 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
UCAR PE vs Consumer Cyclical Sector
UCAR has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has stronger trend alignment. AMZN is above 5 of 5 weekly averages versus UCAR above 0 of 4.
UCAR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 17% below |
| 20 week MA | $10.6 | 72% below |
| 50 week MA | $101.2 | 97% below |
| 100 week MA | $366.9 | 99% below |
UCAR is in a downtrend: it's below all four of its weekly moving averages, and 99% below its 100-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over UCAR on returns for 2026, with the stronger performance.
UCAR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $156,600.0 | $3,670.0 | -98% |
| 2024 | $3,670.0 | $1,326.0 | -64% |
| 2025 | $1,326.0 | $338.0 | -75% |
| 2026 YTD | $338.0 | $2.93 | -99% |
UCAR has finished every year since 2023 lower, and it's down 99% so far in 2026.